Experience of using сrizotinib in patients with ALKpositive non-small cell lung cancer

by E. V. Reutova, L. V. Laktionova, D. T. Marinov, D. A. Peregudov, T. N. Borisova
Published 2020-07-01

Phenotypic transformation as a cause of secondary drug resistance to osimetinib clinical observation

by L. A. Nelyubina, E. V. Reutova, K. K. Laktionov, D. I. Yudin, D. T. Marinov, E. N. Kozak, V. V. Mochalnikova
Published 2018-11-01

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation

by K. K. Laktionov, D. I. Yudin, V. V. Breder, E. V. Reutova, K. P. Laktionov, D. T. Marinov, D. A. Peregudov, M. S. Ardzinba
Published 2019-06-01

THE FIRST CLINICAL EXPERIENCE WITH AFATINIB IN RUSSIAN FEDERATION

by К. К. LAKTIONOV, М. V. PEREGUDOVA, V. V. BREDER, E. V. REUTOVA, D. A. PEREGUDOV, M. S. ARDZINBA, P. A. CHERNENKO, D. T. MARINOV
Published 2016-12-01

Intermediate results of combination therapy in patients with oligometastatic non-small cell lung cancer

by D. I. Yudin, K. K. Laktionov, D. T. Marinov, V. V. Breder, A. K. Allakhverdiev, T. N. Borisova, A. H. Bekyashev, K. P. Laktionov, V. A. Aleshin, M. S. Ardzinba
Published 2018-11-01

Stereotactic hypofractive radiotherapy in the treatment of patients with lung cancer

by T. N. Borisova, A. V. Nazarenko, K. K. Laktionov, S. I. Tkachev, S. B. Alieva, V. V. Breder, O. P. Trofimova, V. V. Glebovskaya, A. A. Fedorova, D. T. Marinov, N. A. Meshcheriakova, S. M. Ivanov, S. G. Gerasimov
Published 2020-12-01